Skip to main content
. 2022 Jul 12;4(9):e582–e585. doi: 10.1016/S2665-9913(22)00190-4

Table.

Factors associated with SARS-CoV-2 infection after vaccination in patients with SLE

SARS-CoV-2 infection (n=44) No SARS-CoV-2 infection (n=119) p value
Received additional vaccine dose 28 (64%) 97 (82%) 0·022
Time from terminal vaccine dose to infection or last follow-up, days 142·1 (87·8) 164·7 (88·8) 0·14
Age, years 42·6 (12·6) 44·7 (13·9) 0·43
Sex
Female 41 (93%) 108 (91%) 0·76
Male 3 (7%) 11 (9%) ..
Race
White 26 (59%) 38 (32%) 0·0020
Black 5 (11%) 34 (29%) ..
Asian 9 (20%) 30 (25%) ..
Other 4 (9%) 17 (14%) ..
Ethnicity
Hispanic or Latinx 17 (39%) 39 (33%) 0·58
Non-Hispanic or Latinx 27 (61%) 80 (67%) ..
Initial mRNA COVID-19 vaccine 42 (95%) 115 (97%) 0·66
Initial vector-based vaccine 2 (5%) 4 (3%) ..
History of lupus nephritis 22 (50) 58 (49%) 1·0
Medications at time of last vaccine
Hydroxychloroquine 40 (91%) 100 (84%) 0·32
Glucocorticoids 14 (32%) 42 (35%) 0·85
≥1 immunosuppressant 24 (55%) 59 (50%) 0·60
Glucocorticoids plus immunosuppressant 13 (30%) 34 (29%) 1·00
Combination of immunosuppressants 11 (25%) 17 (14%) 0·16
COVID-19 treatment
Monoclonal antibodies 3 (7%) NA ..
Ritonavir-boosted nirmatrelvir 3 (7%) NA ..
Remdesivir 1 (2%) NA ..

Data are n (%) or mean (SD). SLE=systemic lupus erythematosus. NA=not applicable.